CA-125 levels are predictive of survival in low-grade serous ovarian cancer—A multicenter analysis
Wohlmuth, Christoph; Djedovic, Vladimir; Kjær, Susanne K.; Jensen, Allan; Glasspool, Rosalind; Roxburgh, Patricia; Defazio, Anna; Johnatty, Sharon E.; Webb, Penelope M.; Modugno, Francesmary; Lambrechts, Diether; Schildkraut, Joellen M.; Berchuck, Andrew; Thomsen, Liv Cecilie Vestrheim; Bjørge, Line; Høgdall, Estrid; Høgdall, Claus K.; Goode, Ellen L.; Winham, Stacey J.; Matsuo, Keitaro; Karlan, Beth Y.; Lester, Jenny; Goodman, Marc T.; Thompson, Pamela J.; Pejovic, Tanja; Riggan, Marjorie J.; Lajkosz, Katherine; Tone, Alicia; May, Taymaa
Journal article, Peer reviewed
MetadataVis full innførsel
OriginalversjonCancers. 2022, 14 (8), 1954. 10.3390/cancers14081954
Objective: Studies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC. Methods: Women with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated. Results: A total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96–1.01 and 0.98; 95%CI 0.95–1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43–12.73) and OS (HR 1.69, 95%CI 0.56–5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36–5.81) and OS (HR 6.62, 95%CI 2.45–17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85). Conclusion: Advanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS. Highlights: 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival.